nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CYP3A4—type 2 diabetes mellitus	0.0681	1	CbGaD
Nilotinib—UGT1A1—Losartan—type 2 diabetes mellitus	0.0262	0.0597	CbGbCtD
Nilotinib—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0227	0.0517	CbGbCtD
Nilotinib—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0181	0.0413	CbGbCtD
Nilotinib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0172	0.0393	CbGbCtD
Nilotinib—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.0164	0.0374	CbGbCtD
Nilotinib—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.0158	0.036	CbGbCtD
Nilotinib—ABCG2—Glyburide—type 2 diabetes mellitus	0.0158	0.0359	CbGbCtD
Nilotinib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0154	0.035	CbGbCtD
Nilotinib—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.0151	0.0345	CbGbCtD
Nilotinib—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.0146	0.0333	CbGbCtD
Nilotinib—CYP2C9—Glipizide—type 2 diabetes mellitus	0.0145	0.033	CbGbCtD
Nilotinib—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.0135	0.0307	CbGbCtD
Nilotinib—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.0119	0.0272	CbGbCtD
Nilotinib—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.0114	0.0261	CbGbCtD
Nilotinib—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.0114	0.0261	CbGbCtD
Nilotinib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0111	0.0253	CbGbCtD
Nilotinib—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.0106	0.0241	CbGbCtD
Nilotinib—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0105	0.0238	CbGbCtD
Nilotinib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0103	0.0235	CbGbCtD
Nilotinib—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.0102	0.0232	CbGbCtD
Nilotinib—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00966	0.022	CbGbCtD
Nilotinib—CYP2C9—Valsartan—type 2 diabetes mellitus	0.00933	0.0212	CbGbCtD
Nilotinib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00921	0.021	CbGbCtD
Nilotinib—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.00868	0.0198	CbGbCtD
Nilotinib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00842	0.0192	CbGbCtD
Nilotinib—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.00832	0.0189	CbGbCtD
Nilotinib—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00793	0.0181	CbGbCtD
Nilotinib—CYP2C8—Losartan—type 2 diabetes mellitus	0.00768	0.0175	CbGbCtD
Nilotinib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00763	0.0174	CbGbCtD
Nilotinib—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00761	0.0173	CbGbCtD
Nilotinib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00736	0.0168	CbGbCtD
Nilotinib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00666	0.0152	CbGbCtD
Nilotinib—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00586	0.0133	CbGbCtD
Nilotinib—ABCB1—Glyburide—type 2 diabetes mellitus	0.00569	0.0129	CbGbCtD
Nilotinib—MAPK8—brown adipose tissue—type 2 diabetes mellitus	0.00562	0.0634	CbGeAlD
Nilotinib—CYP2C9—Losartan—type 2 diabetes mellitus	0.00536	0.0122	CbGbCtD
Nilotinib—ABCB1—Losartan—type 2 diabetes mellitus	0.0052	0.0118	CbGbCtD
Nilotinib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00504	0.0115	CbGbCtD
Nilotinib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00484	0.011	CbGbCtD
Nilotinib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00484	0.011	CbGbCtD
Nilotinib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00457	0.0104	CbGbCtD
Nilotinib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00341	0.00776	CbGbCtD
Nilotinib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00312	0.0071	CbGbCtD
Nilotinib—PDGFRA—penis—type 2 diabetes mellitus	0.00279	0.0315	CbGeAlD
Nilotinib—MAPK8—artery—type 2 diabetes mellitus	0.00247	0.0279	CbGeAlD
Nilotinib—MAPK8—endothelium—type 2 diabetes mellitus	0.00209	0.0236	CbGeAlD
Nilotinib—EPHB3—nerve—type 2 diabetes mellitus	0.00202	0.0229	CbGeAlD
Nilotinib—TIE1—endothelium—type 2 diabetes mellitus	0.00181	0.0205	CbGeAlD
Nilotinib—Ponatinib—SRC—type 2 diabetes mellitus	0.0018	0.569	CrCbGaD
Nilotinib—EPHA4—nerve—type 2 diabetes mellitus	0.00169	0.0191	CbGeAlD
Nilotinib—TEK—artery—type 2 diabetes mellitus	0.00143	0.0161	CbGeAlD
Nilotinib—CDC42BPB—islet of Langerhans—type 2 diabetes mellitus	0.00131	0.0148	CbGeAlD
Nilotinib—EPHB2—retina—type 2 diabetes mellitus	0.00127	0.0144	CbGeAlD
Nilotinib—EPHB4—endothelium—type 2 diabetes mellitus	0.00126	0.0142	CbGeAlD
Nilotinib—TEK—endothelium—type 2 diabetes mellitus	0.0012	0.0136	CbGeAlD
Nilotinib—MAPK8—islet of Langerhans—type 2 diabetes mellitus	0.00119	0.0134	CbGeAlD
Nilotinib—CDC42BPB—retina—type 2 diabetes mellitus	0.00112	0.0127	CbGeAlD
Nilotinib—EPHA3—retina—type 2 diabetes mellitus	0.00107	0.012	CbGeAlD
Nilotinib—MAPK8—retina—type 2 diabetes mellitus	0.00102	0.0115	CbGeAlD
Nilotinib—CDC42BPB—cardiovascular system—type 2 diabetes mellitus	0.000951	0.0107	CbGeAlD
Nilotinib—CA1—nerve—type 2 diabetes mellitus	0.000937	0.0106	CbGeAlD
Nilotinib—MAP4K1—retina—type 2 diabetes mellitus	0.000924	0.0104	CbGeAlD
Nilotinib—CDC42BPB—cortex of kidney—type 2 diabetes mellitus	0.000906	0.0102	CbGeAlD
Nilotinib—KIT—endothelium—type 2 diabetes mellitus	0.000872	0.00985	CbGeAlD
Nilotinib—MAPK8—cardiovascular system—type 2 diabetes mellitus	0.00086	0.00971	CbGeAlD
Nilotinib—MAPK11—adipose tissue—type 2 diabetes mellitus	0.000845	0.00954	CbGeAlD
Nilotinib—MAPK8—kidney—type 2 diabetes mellitus	0.000841	0.0095	CbGeAlD
Nilotinib—CDC42BPB—adipose tissue—type 2 diabetes mellitus	0.000839	0.00947	CbGeAlD
Nilotinib—MAPK8—pancreas—type 2 diabetes mellitus	0.000836	0.00944	CbGeAlD
Nilotinib—MAPK8—cortex of kidney—type 2 diabetes mellitus	0.000819	0.00925	CbGeAlD
Nilotinib—EPHA3—adipose tissue—type 2 diabetes mellitus	0.000795	0.00897	CbGeAlD
Nilotinib—CA9—islet of Langerhans—type 2 diabetes mellitus	0.000774	0.00874	CbGeAlD
Nilotinib—MAPK8—adipose tissue—type 2 diabetes mellitus	0.000758	0.00856	CbGeAlD
Nilotinib—TIE1—cardiovascular system—type 2 diabetes mellitus	0.000746	0.00842	CbGeAlD
Nilotinib—CA4—nerve—type 2 diabetes mellitus	0.000732	0.00827	CbGeAlD
Nilotinib—EPHB4—islet of Langerhans—type 2 diabetes mellitus	0.000716	0.00808	CbGeAlD
Nilotinib—EPHA2—islet of Langerhans—type 2 diabetes mellitus	0.000702	0.00793	CbGeAlD
Nilotinib—FRK—liver—type 2 diabetes mellitus	0.000697	0.00787	CbGeAlD
Nilotinib—MAP4K1—adipose tissue—type 2 diabetes mellitus	0.000689	0.00778	CbGeAlD
Nilotinib—TIE1—adipose tissue—type 2 diabetes mellitus	0.000658	0.00742	CbGeAlD
Nilotinib—EPHB6—islet of Langerhans—type 2 diabetes mellitus	0.000655	0.00739	CbGeAlD
Nilotinib—BRAF—adipose tissue—type 2 diabetes mellitus	0.00063	0.00712	CbGeAlD
Nilotinib—CA7—kidney—type 2 diabetes mellitus	0.000624	0.00704	CbGeAlD
Nilotinib—CDC42BPB—liver—type 2 diabetes mellitus	0.000588	0.00664	CbGeAlD
Nilotinib—CA3—cardiovascular system—type 2 diabetes mellitus	0.000585	0.0066	CbGeAlD
Nilotinib—EPHB4—nephron tubule—type 2 diabetes mellitus	0.000576	0.00651	CbGeAlD
Nilotinib—HCK—adipose tissue—type 2 diabetes mellitus	0.000575	0.00649	CbGeAlD
Nilotinib—ABL2—adipose tissue—type 2 diabetes mellitus	0.000571	0.00645	CbGeAlD
Nilotinib—EPHA2—nephron tubule—type 2 diabetes mellitus	0.000565	0.00638	CbGeAlD
Nilotinib—MAPK14—cardiovascular system—type 2 diabetes mellitus	0.000546	0.00616	CbGeAlD
Nilotinib—FGR—cardiovascular system—type 2 diabetes mellitus	0.000544	0.00614	CbGeAlD
Nilotinib—MAPK14—kidney—type 2 diabetes mellitus	0.000534	0.00603	CbGeAlD
Nilotinib—MAPK8—liver—type 2 diabetes mellitus	0.000532	0.006	CbGeAlD
Nilotinib—EPHA4—adipose tissue—type 2 diabetes mellitus	0.000522	0.0059	CbGeAlD
Nilotinib—EPHB4—cardiovascular system—type 2 diabetes mellitus	0.000518	0.00584	CbGeAlD
Nilotinib—CA3—adipose tissue—type 2 diabetes mellitus	0.000516	0.00582	CbGeAlD
Nilotinib—EPHA2—cardiovascular system—type 2 diabetes mellitus	0.000508	0.00573	CbGeAlD
Nilotinib—EPHB4—kidney—type 2 diabetes mellitus	0.000507	0.00572	CbGeAlD
Nilotinib—EPHB4—pancreas—type 2 diabetes mellitus	0.000503	0.00568	CbGeAlD
Nilotinib—TEK—cardiovascular system—type 2 diabetes mellitus	0.000495	0.00559	CbGeAlD
Nilotinib—EPHA2—pancreas—type 2 diabetes mellitus	0.000494	0.00557	CbGeAlD
Nilotinib—EPHB4—cortex of kidney—type 2 diabetes mellitus	0.000493	0.00557	CbGeAlD
Nilotinib—LYN—liver—type 2 diabetes mellitus	0.000491	0.00554	CbGeAlD
Nilotinib—TEK—kidney—type 2 diabetes mellitus	0.000485	0.00547	CbGeAlD
Nilotinib—PDGFRB—islet of Langerhans—type 2 diabetes mellitus	0.000485	0.00547	CbGeAlD
Nilotinib—MAPK14—adipose tissue—type 2 diabetes mellitus	0.000482	0.00544	CbGeAlD
Nilotinib—TEK—pancreas—type 2 diabetes mellitus	0.000482	0.00544	CbGeAlD
Nilotinib—FGR—adipose tissue—type 2 diabetes mellitus	0.00048	0.00541	CbGeAlD
Nilotinib—LCK—adipose tissue—type 2 diabetes mellitus	0.00048	0.00541	CbGeAlD
Nilotinib—TEK—cortex of kidney—type 2 diabetes mellitus	0.000472	0.00533	CbGeAlD
Nilotinib—TIE1—liver—type 2 diabetes mellitus	0.000461	0.0052	CbGeAlD
Nilotinib—EPHB4—adipose tissue—type 2 diabetes mellitus	0.000457	0.00515	CbGeAlD
Nilotinib—EPHB6—cortex of kidney—type 2 diabetes mellitus	0.000451	0.00509	CbGeAlD
Nilotinib—PDGFRA—cardiovascular system—type 2 diabetes mellitus	0.000449	0.00507	CbGeAlD
Nilotinib—EPHA2—adipose tissue—type 2 diabetes mellitus	0.000448	0.00506	CbGeAlD
Nilotinib—BRAF—liver—type 2 diabetes mellitus	0.000442	0.00499	CbGeAlD
Nilotinib—Ponatinib—CYP3A4—type 2 diabetes mellitus	0.000442	0.14	CrCbGaD
Nilotinib—TEK—adipose tissue—type 2 diabetes mellitus	0.000437	0.00493	CbGeAlD
Nilotinib—ABL1—islet of Langerhans—type 2 diabetes mellitus	0.000432	0.00488	CbGeAlD
Nilotinib—UGT1A1—kidney—type 2 diabetes mellitus	0.000419	0.00473	CbGeAlD
Nilotinib—EPHB6—adipose tissue—type 2 diabetes mellitus	0.000418	0.00471	CbGeAlD
Nilotinib—Imatinib—CYP1A2—type 2 diabetes mellitus	0.000411	0.13	CrCbGaD
Nilotinib—CA12—kidney—type 2 diabetes mellitus	0.000405	0.00458	CbGeAlD
Nilotinib—MAP2K5—cardiovascular system—type 2 diabetes mellitus	0.000405	0.00457	CbGeAlD
Nilotinib—HCK—liver—type 2 diabetes mellitus	0.000403	0.00455	CbGeAlD
Nilotinib—ABL2—liver—type 2 diabetes mellitus	0.000401	0.00452	CbGeAlD
Nilotinib—KIT—nephron tubule—type 2 diabetes mellitus	0.0004	0.00451	CbGeAlD
Nilotinib—PDGFRA—adipose tissue—type 2 diabetes mellitus	0.000396	0.00447	CbGeAlD
Nilotinib—CSF1R—cardiovascular system—type 2 diabetes mellitus	0.000395	0.00446	CbGeAlD
Nilotinib—MAP2K5—cortex of kidney—type 2 diabetes mellitus	0.000386	0.00436	CbGeAlD
Nilotinib—ABL1—retina—type 2 diabetes mellitus	0.000369	0.00417	CbGeAlD
Nilotinib—CA3—liver—type 2 diabetes mellitus	0.000362	0.00408	CbGeAlD
Nilotinib—KIT—cardiovascular system—type 2 diabetes mellitus	0.000359	0.00405	CbGeAlD
Nilotinib—MAP2K5—adipose tissue—type 2 diabetes mellitus	0.000357	0.00403	CbGeAlD
Nilotinib—CA4—islet of Langerhans—type 2 diabetes mellitus	0.000355	0.004	CbGeAlD
Nilotinib—KIT—kidney—type 2 diabetes mellitus	0.000351	0.00396	CbGeAlD
Nilotinib—PDGFRB—cardiovascular system—type 2 diabetes mellitus	0.000351	0.00396	CbGeAlD
Nilotinib—KIT—pancreas—type 2 diabetes mellitus	0.000349	0.00394	CbGeAlD
Nilotinib—CSF1R—adipose tissue—type 2 diabetes mellitus	0.000349	0.00393	CbGeAlD
Nilotinib—ABL1—nephron tubule—type 2 diabetes mellitus	0.000348	0.00393	CbGeAlD
Nilotinib—PDGFRB—kidney—type 2 diabetes mellitus	0.000343	0.00387	CbGeAlD
Nilotinib—KIT—cortex of kidney—type 2 diabetes mellitus	0.000342	0.00386	CbGeAlD
Nilotinib—PDGFRB—pancreas—type 2 diabetes mellitus	0.000341	0.00385	CbGeAlD
Nilotinib—MAPK14—liver—type 2 diabetes mellitus	0.000338	0.00381	CbGeAlD
Nilotinib—FGR—liver—type 2 diabetes mellitus	0.000336	0.0038	CbGeAlD
Nilotinib—LCK—liver—type 2 diabetes mellitus	0.000336	0.0038	CbGeAlD
Nilotinib—PDGFRB—cortex of kidney—type 2 diabetes mellitus	0.000334	0.00377	CbGeAlD
Nilotinib—CA14—liver—type 2 diabetes mellitus	0.000329	0.00371	CbGeAlD
Nilotinib—CA1—cardiovascular system—type 2 diabetes mellitus	0.000328	0.0037	CbGeAlD
Nilotinib—CA1—kidney—type 2 diabetes mellitus	0.000321	0.00363	CbGeAlD
Nilotinib—EPHB4—liver—type 2 diabetes mellitus	0.00032	0.00361	CbGeAlD
Nilotinib—CA1—pancreas—type 2 diabetes mellitus	0.000319	0.0036	CbGeAlD
Nilotinib—KIT—adipose tissue—type 2 diabetes mellitus	0.000316	0.00357	CbGeAlD
Nilotinib—EPHA2—liver—type 2 diabetes mellitus	0.000314	0.00355	CbGeAlD
Nilotinib—ABL1—cardiovascular system—type 2 diabetes mellitus	0.000312	0.00353	CbGeAlD
Nilotinib—PDGFRB—adipose tissue—type 2 diabetes mellitus	0.000309	0.00349	CbGeAlD
Nilotinib—TEK—liver—type 2 diabetes mellitus	0.000306	0.00346	CbGeAlD
Nilotinib—ABL1—kidney—type 2 diabetes mellitus	0.000306	0.00345	CbGeAlD
Nilotinib—ABL1—pancreas—type 2 diabetes mellitus	0.000304	0.00343	CbGeAlD
Nilotinib—ABL1—cortex of kidney—type 2 diabetes mellitus	0.000298	0.00336	CbGeAlD
Nilotinib—CA2—islet of Langerhans—type 2 diabetes mellitus	0.000294	0.00332	CbGeAlD
Nilotinib—CA1—adipose tissue—type 2 diabetes mellitus	0.000289	0.00327	CbGeAlD
Nilotinib—CA4—nephron tubule—type 2 diabetes mellitus	0.000286	0.00322	CbGeAlD
Nilotinib—PDGFRA—liver—type 2 diabetes mellitus	0.000278	0.00313	CbGeAlD
Nilotinib—ABL1—adipose tissue—type 2 diabetes mellitus	0.000275	0.00311	CbGeAlD
Nilotinib—Imatinib—CYP3A4—type 2 diabetes mellitus	0.000272	0.086	CrCbGaD
Nilotinib—UGT1A1—liver—type 2 diabetes mellitus	0.000265	0.00299	CbGeAlD
Nilotinib—CA4—cardiovascular system—type 2 diabetes mellitus	0.000257	0.0029	CbGeAlD
Nilotinib—CA2—retina—type 2 diabetes mellitus	0.000251	0.00284	CbGeAlD
Nilotinib—CA4—kidney—type 2 diabetes mellitus	0.000251	0.00283	CbGeAlD
Nilotinib—MAP2K5—liver—type 2 diabetes mellitus	0.00025	0.00283	CbGeAlD
Nilotinib—CA4—cortex of kidney—type 2 diabetes mellitus	0.000244	0.00276	CbGeAlD
Nilotinib—CSF1R—liver—type 2 diabetes mellitus	0.000244	0.00276	CbGeAlD
Nilotinib—Imatinib—ALB—type 2 diabetes mellitus	0.000237	0.075	CrCbGaD
Nilotinib—CA2—nephron tubule—type 2 diabetes mellitus	0.000237	0.00267	CbGeAlD
Nilotinib—CA4—adipose tissue—type 2 diabetes mellitus	0.000226	0.00255	CbGeAlD
Nilotinib—KIT—liver—type 2 diabetes mellitus	0.000222	0.00251	CbGeAlD
Nilotinib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000219	0.00248	CbGeAlD
Nilotinib—PDGFRB—liver—type 2 diabetes mellitus	0.000217	0.00245	CbGeAlD
Nilotinib—CA2—cardiovascular system—type 2 diabetes mellitus	0.000213	0.0024	CbGeAlD
Nilotinib—CA2—kidney—type 2 diabetes mellitus	0.000208	0.00235	CbGeAlD
Nilotinib—CA2—pancreas—type 2 diabetes mellitus	0.000207	0.00233	CbGeAlD
Nilotinib—CA1—liver—type 2 diabetes mellitus	0.000203	0.00229	CbGeAlD
Nilotinib—CA2—cortex of kidney—type 2 diabetes mellitus	0.000203	0.00229	CbGeAlD
Nilotinib—CYP2B6—nephron tubule—type 2 diabetes mellitus	0.000202	0.00228	CbGeAlD
Nilotinib—CYP2C8—kidney—type 2 diabetes mellitus	0.000198	0.00224	CbGeAlD
Nilotinib—ABL1—liver—type 2 diabetes mellitus	0.000193	0.00218	CbGeAlD
Nilotinib—CA2—adipose tissue—type 2 diabetes mellitus	0.000188	0.00212	CbGeAlD
Nilotinib—CYP2B6—cardiovascular system—type 2 diabetes mellitus	0.000182	0.00205	CbGeAlD
Nilotinib—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.00018	0.00203	CbGeAlD
Nilotinib—CYP2B6—kidney—type 2 diabetes mellitus	0.000178	0.00201	CbGeAlD
Nilotinib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000174	0.00196	CbGeAlD
Nilotinib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000134	0.00152	CbGeAlD
Nilotinib—CYP3A4—kidney—type 2 diabetes mellitus	0.000134	0.00152	CbGeAlD
Nilotinib—CYP2D6—kidney—type 2 diabetes mellitus	0.000132	0.00149	CbGeAlD
Nilotinib—CA2—liver—type 2 diabetes mellitus	0.000132	0.00149	CbGeAlD
Nilotinib—CYP2C8—liver—type 2 diabetes mellitus	0.000125	0.00141	CbGeAlD
Nilotinib—ABCG2—liver—type 2 diabetes mellitus	0.000122	0.00138	CbGeAlD
Nilotinib—ABCB1—retina—type 2 diabetes mellitus	0.000115	0.0013	CbGeAlD
Nilotinib—CYP2B6—liver—type 2 diabetes mellitus	0.000112	0.00127	CbGeAlD
Nilotinib—CYP2C9—liver—type 2 diabetes mellitus	0.000111	0.00126	CbGeAlD
Nilotinib—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000108	0.00122	CbGeAlD
Nilotinib—ABCB1—cardiovascular system—type 2 diabetes mellitus	9.71e-05	0.0011	CbGeAlD
Nilotinib—ABCB1—kidney—type 2 diabetes mellitus	9.51e-05	0.00107	CbGeAlD
Nilotinib—ABCB1—pancreas—type 2 diabetes mellitus	9.44e-05	0.00107	CbGeAlD
Nilotinib—ABCB1—cortex of kidney—type 2 diabetes mellitus	9.26e-05	0.00104	CbGeAlD
Nilotinib—ABCB1—adipose tissue—type 2 diabetes mellitus	8.57e-05	0.000967	CbGeAlD
Nilotinib—CYP3A4—liver—type 2 diabetes mellitus	8.49e-05	0.000958	CbGeAlD
Nilotinib—CYP2D6—liver—type 2 diabetes mellitus	8.35e-05	0.000943	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	6.93e-05	0.000327	CcSEcCtD
Nilotinib—Paraesthesia—Valsartan—type 2 diabetes mellitus	6.91e-05	0.000326	CcSEcCtD
Nilotinib—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	6.9e-05	0.000325	CcSEcCtD
Nilotinib—Chest pain—Irbesartan—type 2 diabetes mellitus	6.9e-05	0.000325	CcSEcCtD
Nilotinib—Myalgia—Irbesartan—type 2 diabetes mellitus	6.9e-05	0.000325	CcSEcCtD
Nilotinib—Arthralgia—Irbesartan—type 2 diabetes mellitus	6.9e-05	0.000325	CcSEcCtD
Nilotinib—Shock—Metformin—type 2 diabetes mellitus	6.9e-05	0.000325	CcSEcCtD
Nilotinib—Insomnia—Orlistat—type 2 diabetes mellitus	6.88e-05	0.000324	CcSEcCtD
Nilotinib—Malaise—Losartan—type 2 diabetes mellitus	6.88e-05	0.000324	CcSEcCtD
Nilotinib—Anxiety—Irbesartan—type 2 diabetes mellitus	6.88e-05	0.000324	CcSEcCtD
Nilotinib—Hypersensitivity—Glyburide—type 2 diabetes mellitus	6.87e-05	0.000324	CcSEcCtD
Nilotinib—Nervous system disorder—Metformin—type 2 diabetes mellitus	6.87e-05	0.000324	CcSEcCtD
Nilotinib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	6.86e-05	0.000324	CcSEcCtD
Nilotinib—Dyspnoea—Valsartan—type 2 diabetes mellitus	6.86e-05	0.000324	CcSEcCtD
Nilotinib—Vertigo—Losartan—type 2 diabetes mellitus	6.85e-05	0.000323	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	6.85e-05	0.000323	CcSEcCtD
Nilotinib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	6.85e-05	0.000323	CcSEcCtD
Nilotinib—Syncope—Losartan—type 2 diabetes mellitus	6.84e-05	0.000322	CcSEcCtD
Nilotinib—Paraesthesia—Orlistat—type 2 diabetes mellitus	6.83e-05	0.000322	CcSEcCtD
Nilotinib—Leukopenia—Losartan—type 2 diabetes mellitus	6.83e-05	0.000322	CcSEcCtD
Nilotinib—Discomfort—Irbesartan—type 2 diabetes mellitus	6.82e-05	0.000321	CcSEcCtD
Nilotinib—Skin disorder—Metformin—type 2 diabetes mellitus	6.81e-05	0.000321	CcSEcCtD
Nilotinib—Immune system disorder—Ramipril—type 2 diabetes mellitus	6.79e-05	0.00032	CcSEcCtD
Nilotinib—Hyperhidrosis—Metformin—type 2 diabetes mellitus	6.78e-05	0.000319	CcSEcCtD
Nilotinib—Dyspepsia—Valsartan—type 2 diabetes mellitus	6.77e-05	0.000319	CcSEcCtD
Nilotinib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	6.77e-05	0.000319	CcSEcCtD
Nilotinib—Dizziness—Bromocriptine—type 2 diabetes mellitus	6.75e-05	0.000318	CcSEcCtD
Nilotinib—Dry mouth—Irbesartan—type 2 diabetes mellitus	6.75e-05	0.000318	CcSEcCtD
Nilotinib—Palpitations—Losartan—type 2 diabetes mellitus	6.74e-05	0.000318	CcSEcCtD
Nilotinib—Nausea—Glimepiride—type 2 diabetes mellitus	6.72e-05	0.000317	CcSEcCtD
Nilotinib—Arrhythmia—Ramipril—type 2 diabetes mellitus	6.71e-05	0.000316	CcSEcCtD
Nilotinib—Loss of consciousness—Losartan—type 2 diabetes mellitus	6.7e-05	0.000316	CcSEcCtD
Nilotinib—Nausea—Sitagliptin—type 2 diabetes mellitus	6.7e-05	0.000316	CcSEcCtD
Nilotinib—Dyspepsia—Orlistat—type 2 diabetes mellitus	6.69e-05	0.000316	CcSEcCtD
Nilotinib—Asthenia—Glyburide—type 2 diabetes mellitus	6.69e-05	0.000316	CcSEcCtD
Nilotinib—Decreased appetite—Valsartan—type 2 diabetes mellitus	6.69e-05	0.000315	CcSEcCtD
Nilotinib—Anorexia—Metformin—type 2 diabetes mellitus	6.68e-05	0.000315	CcSEcCtD
Nilotinib—Cough—Losartan—type 2 diabetes mellitus	6.66e-05	0.000314	CcSEcCtD
Nilotinib—Urticaria—Gliclazide—type 2 diabetes mellitus	6.65e-05	0.000314	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	6.64e-05	0.000313	CcSEcCtD
Nilotinib—Alopecia—Ramipril—type 2 diabetes mellitus	6.64e-05	0.000313	CcSEcCtD
Nilotinib—Fatigue—Valsartan—type 2 diabetes mellitus	6.64e-05	0.000313	CcSEcCtD
Nilotinib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	6.62e-05	0.000312	CcSEcCtD
Nilotinib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	6.62e-05	0.000312	CcSEcCtD
Nilotinib—Oedema—Irbesartan—type 2 diabetes mellitus	6.61e-05	0.000312	CcSEcCtD
Nilotinib—Decreased appetite—Orlistat—type 2 diabetes mellitus	6.61e-05	0.000312	CcSEcCtD
Nilotinib—Pruritus—Glyburide—type 2 diabetes mellitus	6.6e-05	0.000311	CcSEcCtD
Nilotinib—Mental disorder—Ramipril—type 2 diabetes mellitus	6.58e-05	0.00031	CcSEcCtD
Nilotinib—Constipation—Valsartan—type 2 diabetes mellitus	6.58e-05	0.00031	CcSEcCtD
Nilotinib—Infection—Irbesartan—type 2 diabetes mellitus	6.57e-05	0.00031	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	6.57e-05	0.00031	CcSEcCtD
Nilotinib—Fatigue—Orlistat—type 2 diabetes mellitus	6.56e-05	0.000309	CcSEcCtD
Nilotinib—Hypotension—Metformin—type 2 diabetes mellitus	6.55e-05	0.000309	CcSEcCtD
Nilotinib—Malnutrition—Ramipril—type 2 diabetes mellitus	6.54e-05	0.000308	CcSEcCtD
Nilotinib—Erythema—Ramipril—type 2 diabetes mellitus	6.54e-05	0.000308	CcSEcCtD
Nilotinib—Shock—Irbesartan—type 2 diabetes mellitus	6.51e-05	0.000307	CcSEcCtD
Nilotinib—Pain—Orlistat—type 2 diabetes mellitus	6.5e-05	0.000307	CcSEcCtD
Nilotinib—Myalgia—Losartan—type 2 diabetes mellitus	6.49e-05	0.000306	CcSEcCtD
Nilotinib—Chest pain—Losartan—type 2 diabetes mellitus	6.49e-05	0.000306	CcSEcCtD
Nilotinib—Arthralgia—Losartan—type 2 diabetes mellitus	6.49e-05	0.000306	CcSEcCtD
Nilotinib—Vomiting—Bromocriptine—type 2 diabetes mellitus	6.49e-05	0.000306	CcSEcCtD
Nilotinib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	6.49e-05	0.000306	CcSEcCtD
Nilotinib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	6.48e-05	0.000305	CcSEcCtD
Nilotinib—Anxiety—Losartan—type 2 diabetes mellitus	6.47e-05	0.000305	CcSEcCtD
Nilotinib—Tachycardia—Irbesartan—type 2 diabetes mellitus	6.46e-05	0.000304	CcSEcCtD
Nilotinib—Rash—Bromocriptine—type 2 diabetes mellitus	6.43e-05	0.000303	CcSEcCtD
Nilotinib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.43e-05	0.000303	CcSEcCtD
Nilotinib—Skin disorder—Irbesartan—type 2 diabetes mellitus	6.42e-05	0.000303	CcSEcCtD
Nilotinib—Discomfort—Losartan—type 2 diabetes mellitus	6.42e-05	0.000302	CcSEcCtD
Nilotinib—Dysgeusia—Ramipril—type 2 diabetes mellitus	6.4e-05	0.000302	CcSEcCtD
Nilotinib—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	6.39e-05	0.000301	CcSEcCtD
Nilotinib—Headache—Bromocriptine—type 2 diabetes mellitus	6.39e-05	0.000301	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.39e-05	0.000301	CcSEcCtD
Nilotinib—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.38e-05	0.000301	CcSEcCtD
Nilotinib—Dry mouth—Losartan—type 2 diabetes mellitus	6.35e-05	0.000299	CcSEcCtD
Nilotinib—Anorexia—Irbesartan—type 2 diabetes mellitus	6.3e-05	0.000297	CcSEcCtD
Nilotinib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	6.29e-05	0.000297	CcSEcCtD
Nilotinib—Paraesthesia—Metformin—type 2 diabetes mellitus	6.29e-05	0.000297	CcSEcCtD
Nilotinib—Muscle spasms—Ramipril—type 2 diabetes mellitus	6.29e-05	0.000296	CcSEcCtD
Nilotinib—Confusional state—Losartan—type 2 diabetes mellitus	6.28e-05	0.000296	CcSEcCtD
Nilotinib—Feeling abnormal—Orlistat—type 2 diabetes mellitus	6.27e-05	0.000295	CcSEcCtD
Nilotinib—Dyspnoea—Metformin—type 2 diabetes mellitus	6.25e-05	0.000295	CcSEcCtD
Nilotinib—Oedema—Losartan—type 2 diabetes mellitus	6.22e-05	0.000293	CcSEcCtD
Nilotinib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	6.22e-05	0.000293	CcSEcCtD
Nilotinib—Infection—Losartan—type 2 diabetes mellitus	6.18e-05	0.000292	CcSEcCtD
Nilotinib—Hypotension—Irbesartan—type 2 diabetes mellitus	6.18e-05	0.000291	CcSEcCtD
Nilotinib—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	6.17e-05	0.000291	CcSEcCtD
Nilotinib—Dyspepsia—Metformin—type 2 diabetes mellitus	6.17e-05	0.000291	CcSEcCtD
Nilotinib—Tremor—Ramipril—type 2 diabetes mellitus	6.13e-05	0.000289	CcSEcCtD
Nilotinib—Shock—Losartan—type 2 diabetes mellitus	6.12e-05	0.000289	CcSEcCtD
Nilotinib—Urticaria—Valsartan—type 2 diabetes mellitus	6.11e-05	0.000288	CcSEcCtD
Nilotinib—Nervous system disorder—Losartan—type 2 diabetes mellitus	6.1e-05	0.000288	CcSEcCtD
Nilotinib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	6.09e-05	0.000287	CcSEcCtD
Nilotinib—Decreased appetite—Metformin—type 2 diabetes mellitus	6.09e-05	0.000287	CcSEcCtD
Nilotinib—Abdominal pain—Valsartan—type 2 diabetes mellitus	6.08e-05	0.000287	CcSEcCtD
Nilotinib—Tachycardia—Losartan—type 2 diabetes mellitus	6.07e-05	0.000286	CcSEcCtD
Nilotinib—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	6.07e-05	0.000286	CcSEcCtD
Nilotinib—Nausea—Bromocriptine—type 2 diabetes mellitus	6.06e-05	0.000286	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	6.05e-05	0.000285	CcSEcCtD
Nilotinib—Fatigue—Metformin—type 2 diabetes mellitus	6.04e-05	0.000285	CcSEcCtD
Nilotinib—Urticaria—Orlistat—type 2 diabetes mellitus	6.04e-05	0.000285	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	6.03e-05	0.000284	CcSEcCtD
Nilotinib—Hyperhidrosis—Losartan—type 2 diabetes mellitus	6.02e-05	0.000284	CcSEcCtD
Nilotinib—Abdominal pain—Orlistat—type 2 diabetes mellitus	6.01e-05	0.000283	CcSEcCtD
Nilotinib—Body temperature increased—Orlistat—type 2 diabetes mellitus	6.01e-05	0.000283	CcSEcCtD
Nilotinib—Asthenia—Gliclazide—type 2 diabetes mellitus	6.01e-05	0.000283	CcSEcCtD
Nilotinib—ABCB1—liver—type 2 diabetes mellitus	6.01e-05	0.000678	CbGeAlD
Nilotinib—Constipation—Metformin—type 2 diabetes mellitus	5.99e-05	0.000283	CcSEcCtD
Nilotinib—Paraesthesia—Irbesartan—type 2 diabetes mellitus	5.94e-05	0.00028	CcSEcCtD
Nilotinib—Anorexia—Losartan—type 2 diabetes mellitus	5.93e-05	0.00028	CcSEcCtD
Nilotinib—Vomiting—Glyburide—type 2 diabetes mellitus	5.93e-05	0.00028	CcSEcCtD
Nilotinib—Pruritus—Gliclazide—type 2 diabetes mellitus	5.93e-05	0.000279	CcSEcCtD
Nilotinib—Malaise—Ramipril—type 2 diabetes mellitus	5.9e-05	0.000278	CcSEcCtD
Nilotinib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	5.9e-05	0.000278	CcSEcCtD
Nilotinib—Rash—Glyburide—type 2 diabetes mellitus	5.88e-05	0.000277	CcSEcCtD
Nilotinib—Dermatitis—Glyburide—type 2 diabetes mellitus	5.88e-05	0.000277	CcSEcCtD
Nilotinib—Vertigo—Ramipril—type 2 diabetes mellitus	5.88e-05	0.000277	CcSEcCtD
Nilotinib—Syncope—Ramipril—type 2 diabetes mellitus	5.86e-05	0.000277	CcSEcCtD
Nilotinib—Leukopenia—Ramipril—type 2 diabetes mellitus	5.85e-05	0.000276	CcSEcCtD
Nilotinib—Headache—Glyburide—type 2 diabetes mellitus	5.84e-05	0.000276	CcSEcCtD
Nilotinib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	5.82e-05	0.000275	CcSEcCtD
Nilotinib—Hypotension—Losartan—type 2 diabetes mellitus	5.82e-05	0.000274	CcSEcCtD
Nilotinib—Palpitations—Ramipril—type 2 diabetes mellitus	5.78e-05	0.000272	CcSEcCtD
Nilotinib—Feeling abnormal—Metformin—type 2 diabetes mellitus	5.78e-05	0.000272	CcSEcCtD
Nilotinib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	5.75e-05	0.000271	CcSEcCtD
Nilotinib—Loss of consciousness—Ramipril—type 2 diabetes mellitus	5.75e-05	0.000271	CcSEcCtD
Nilotinib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.73e-05	0.00027	CcSEcCtD
Nilotinib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	5.73e-05	0.00027	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	5.71e-05	0.000269	CcSEcCtD
Nilotinib—Cough—Ramipril—type 2 diabetes mellitus	5.71e-05	0.000269	CcSEcCtD
Nilotinib—Fatigue—Irbesartan—type 2 diabetes mellitus	5.7e-05	0.000269	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5.67e-05	0.000267	CcSEcCtD
Nilotinib—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5.67e-05	0.000267	CcSEcCtD
Nilotinib—Pain—Irbesartan—type 2 diabetes mellitus	5.66e-05	0.000267	CcSEcCtD
Nilotinib—Constipation—Irbesartan—type 2 diabetes mellitus	5.66e-05	0.000267	CcSEcCtD
Nilotinib—Insomnia—Losartan—type 2 diabetes mellitus	5.63e-05	0.000265	CcSEcCtD
Nilotinib—Hypersensitivity—Orlistat—type 2 diabetes mellitus	5.6e-05	0.000264	CcSEcCtD
Nilotinib—Paraesthesia—Losartan—type 2 diabetes mellitus	5.59e-05	0.000264	CcSEcCtD
Nilotinib—Urticaria—Metformin—type 2 diabetes mellitus	5.57e-05	0.000263	CcSEcCtD
Nilotinib—Myalgia—Ramipril—type 2 diabetes mellitus	5.57e-05	0.000263	CcSEcCtD
Nilotinib—Arthralgia—Ramipril—type 2 diabetes mellitus	5.57e-05	0.000263	CcSEcCtD
Nilotinib—Chest pain—Ramipril—type 2 diabetes mellitus	5.57e-05	0.000263	CcSEcCtD
Nilotinib—Dyspnoea—Losartan—type 2 diabetes mellitus	5.55e-05	0.000262	CcSEcCtD
Nilotinib—Anxiety—Ramipril—type 2 diabetes mellitus	5.55e-05	0.000262	CcSEcCtD
Nilotinib—Nausea—Glyburide—type 2 diabetes mellitus	5.54e-05	0.000261	CcSEcCtD
Nilotinib—Abdominal pain—Metformin—type 2 diabetes mellitus	5.54e-05	0.000261	CcSEcCtD
Nilotinib—Dizziness—Gliclazide—type 2 diabetes mellitus	5.54e-05	0.000261	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	5.53e-05	0.000261	CcSEcCtD
Nilotinib—Asthenia—Valsartan—type 2 diabetes mellitus	5.52e-05	0.00026	CcSEcCtD
Nilotinib—Discomfort—Ramipril—type 2 diabetes mellitus	5.5e-05	0.000259	CcSEcCtD
Nilotinib—Dyspepsia—Losartan—type 2 diabetes mellitus	5.48e-05	0.000258	CcSEcCtD
Nilotinib—Asthenia—Orlistat—type 2 diabetes mellitus	5.46e-05	0.000257	CcSEcCtD
Nilotinib—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	5.45e-05	0.000257	CcSEcCtD
Nilotinib—Pruritus—Valsartan—type 2 diabetes mellitus	5.45e-05	0.000257	CcSEcCtD
Nilotinib—Dry mouth—Ramipril—type 2 diabetes mellitus	5.44e-05	0.000257	CcSEcCtD
Nilotinib—Decreased appetite—Losartan—type 2 diabetes mellitus	5.41e-05	0.000255	CcSEcCtD
Nilotinib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	5.41e-05	0.000255	CcSEcCtD
Nilotinib—Confusional state—Ramipril—type 2 diabetes mellitus	5.38e-05	0.000254	CcSEcCtD
Nilotinib—Pruritus—Orlistat—type 2 diabetes mellitus	5.38e-05	0.000254	CcSEcCtD
Nilotinib—Fatigue—Losartan—type 2 diabetes mellitus	5.37e-05	0.000253	CcSEcCtD
Nilotinib—Oedema—Ramipril—type 2 diabetes mellitus	5.34e-05	0.000252	CcSEcCtD
Nilotinib—Vomiting—Gliclazide—type 2 diabetes mellitus	5.33e-05	0.000251	CcSEcCtD
Nilotinib—Constipation—Losartan—type 2 diabetes mellitus	5.32e-05	0.000251	CcSEcCtD
Nilotinib—Pain—Losartan—type 2 diabetes mellitus	5.32e-05	0.000251	CcSEcCtD
Nilotinib—Rash—Gliclazide—type 2 diabetes mellitus	5.28e-05	0.000249	CcSEcCtD
Nilotinib—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.28e-05	0.000249	CcSEcCtD
Nilotinib—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.27e-05	0.000248	CcSEcCtD
Nilotinib—Urticaria—Irbesartan—type 2 diabetes mellitus	5.25e-05	0.000248	CcSEcCtD
Nilotinib—Shock—Ramipril—type 2 diabetes mellitus	5.25e-05	0.000248	CcSEcCtD
Nilotinib—Headache—Gliclazide—type 2 diabetes mellitus	5.25e-05	0.000247	CcSEcCtD
Nilotinib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	5.23e-05	0.000247	CcSEcCtD
Nilotinib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	5.23e-05	0.000247	CcSEcCtD
Nilotinib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	5.23e-05	0.000247	CcSEcCtD
Nilotinib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	5.23e-05	0.000246	CcSEcCtD
Nilotinib—Tachycardia—Ramipril—type 2 diabetes mellitus	5.21e-05	0.000246	CcSEcCtD
Nilotinib—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.2e-05	0.000245	CcSEcCtD
Nilotinib—Skin disorder—Ramipril—type 2 diabetes mellitus	5.18e-05	0.000244	CcSEcCtD
Nilotinib—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	5.16e-05	0.000243	CcSEcCtD
Nilotinib—Feeling abnormal—Losartan—type 2 diabetes mellitus	5.13e-05	0.000242	CcSEcCtD
Nilotinib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	5.09e-05	0.00024	CcSEcCtD
Nilotinib—Dizziness—Valsartan—type 2 diabetes mellitus	5.09e-05	0.00024	CcSEcCtD
Nilotinib—Anorexia—Ramipril—type 2 diabetes mellitus	5.09e-05	0.00024	CcSEcCtD
Nilotinib—Dizziness—Orlistat—type 2 diabetes mellitus	5.03e-05	0.000237	CcSEcCtD
Nilotinib—Asthenia—Metformin—type 2 diabetes mellitus	5.03e-05	0.000237	CcSEcCtD
Nilotinib—Hypotension—Ramipril—type 2 diabetes mellitus	4.99e-05	0.000235	CcSEcCtD
Nilotinib—Nausea—Gliclazide—type 2 diabetes mellitus	4.98e-05	0.000235	CcSEcCtD
Nilotinib—Pruritus—Metformin—type 2 diabetes mellitus	4.96e-05	0.000234	CcSEcCtD
Nilotinib—Urticaria—Losartan—type 2 diabetes mellitus	4.94e-05	0.000233	CcSEcCtD
Nilotinib—Abdominal pain—Losartan—type 2 diabetes mellitus	4.92e-05	0.000232	CcSEcCtD
Nilotinib—Body temperature increased—Losartan—type 2 diabetes mellitus	4.92e-05	0.000232	CcSEcCtD
Nilotinib—Vomiting—Valsartan—type 2 diabetes mellitus	4.89e-05	0.000231	CcSEcCtD
Nilotinib—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.87e-05	0.00023	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.86e-05	0.000229	CcSEcCtD
Nilotinib—Rash—Valsartan—type 2 diabetes mellitus	4.85e-05	0.000229	CcSEcCtD
Nilotinib—Dermatitis—Valsartan—type 2 diabetes mellitus	4.85e-05	0.000229	CcSEcCtD
Nilotinib—Vomiting—Orlistat—type 2 diabetes mellitus	4.84e-05	0.000228	CcSEcCtD
Nilotinib—Insomnia—Ramipril—type 2 diabetes mellitus	4.83e-05	0.000228	CcSEcCtD
Nilotinib—Headache—Valsartan—type 2 diabetes mellitus	4.82e-05	0.000227	CcSEcCtD
Nilotinib—Diarrhoea—Metformin—type 2 diabetes mellitus	4.8e-05	0.000226	CcSEcCtD
Nilotinib—Rash—Orlistat—type 2 diabetes mellitus	4.79e-05	0.000226	CcSEcCtD
Nilotinib—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.79e-05	0.000226	CcSEcCtD
Nilotinib—Dermatitis—Orlistat—type 2 diabetes mellitus	4.79e-05	0.000226	CcSEcCtD
Nilotinib—Headache—Orlistat—type 2 diabetes mellitus	4.76e-05	0.000225	CcSEcCtD
Nilotinib—Dyspnoea—Ramipril—type 2 diabetes mellitus	4.76e-05	0.000224	CcSEcCtD
Nilotinib—Asthenia—Irbesartan—type 2 diabetes mellitus	4.75e-05	0.000224	CcSEcCtD
Nilotinib—Dyspepsia—Ramipril—type 2 diabetes mellitus	4.7e-05	0.000222	CcSEcCtD
Nilotinib—Pruritus—Irbesartan—type 2 diabetes mellitus	4.68e-05	0.000221	CcSEcCtD
Nilotinib—Decreased appetite—Ramipril—type 2 diabetes mellitus	4.64e-05	0.000219	CcSEcCtD
Nilotinib—Dizziness—Metformin—type 2 diabetes mellitus	4.63e-05	0.000219	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.61e-05	0.000217	CcSEcCtD
Nilotinib—Fatigue—Ramipril—type 2 diabetes mellitus	4.6e-05	0.000217	CcSEcCtD
Nilotinib—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.59e-05	0.000216	CcSEcCtD
Nilotinib—Nausea—Valsartan—type 2 diabetes mellitus	4.57e-05	0.000216	CcSEcCtD
Nilotinib—Constipation—Ramipril—type 2 diabetes mellitus	4.56e-05	0.000215	CcSEcCtD
Nilotinib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.53e-05	0.000213	CcSEcCtD
Nilotinib—Nausea—Orlistat—type 2 diabetes mellitus	4.52e-05	0.000213	CcSEcCtD
Nilotinib—Asthenia—Losartan—type 2 diabetes mellitus	4.47e-05	0.000211	CcSEcCtD
Nilotinib—Vomiting—Metformin—type 2 diabetes mellitus	4.46e-05	0.00021	CcSEcCtD
Nilotinib—Rash—Metformin—type 2 diabetes mellitus	4.42e-05	0.000208	CcSEcCtD
Nilotinib—Dermatitis—Metformin—type 2 diabetes mellitus	4.41e-05	0.000208	CcSEcCtD
Nilotinib—Pruritus—Losartan—type 2 diabetes mellitus	4.4e-05	0.000208	CcSEcCtD
Nilotinib—Feeling abnormal—Ramipril—type 2 diabetes mellitus	4.4e-05	0.000207	CcSEcCtD
Nilotinib—Headache—Metformin—type 2 diabetes mellitus	4.39e-05	0.000207	CcSEcCtD
Nilotinib—Dizziness—Irbesartan—type 2 diabetes mellitus	4.37e-05	0.000206	CcSEcCtD
Nilotinib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	4.36e-05	0.000206	CcSEcCtD
Nilotinib—Diarrhoea—Losartan—type 2 diabetes mellitus	4.26e-05	0.000201	CcSEcCtD
Nilotinib—Urticaria—Ramipril—type 2 diabetes mellitus	4.24e-05	0.0002	CcSEcCtD
Nilotinib—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.22e-05	0.000199	CcSEcCtD
Nilotinib—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.22e-05	0.000199	CcSEcCtD
Nilotinib—Vomiting—Irbesartan—type 2 diabetes mellitus	4.21e-05	0.000198	CcSEcCtD
Nilotinib—Rash—Irbesartan—type 2 diabetes mellitus	4.17e-05	0.000197	CcSEcCtD
Nilotinib—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.17e-05	0.000196	CcSEcCtD
Nilotinib—Nausea—Metformin—type 2 diabetes mellitus	4.16e-05	0.000196	CcSEcCtD
Nilotinib—Headache—Irbesartan—type 2 diabetes mellitus	4.14e-05	0.000195	CcSEcCtD
Nilotinib—Dizziness—Losartan—type 2 diabetes mellitus	4.12e-05	0.000194	CcSEcCtD
Nilotinib—Vomiting—Losartan—type 2 diabetes mellitus	3.96e-05	0.000187	CcSEcCtD
Nilotinib—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.93e-05	0.000185	CcSEcCtD
Nilotinib—Nausea—Irbesartan—type 2 diabetes mellitus	3.93e-05	0.000185	CcSEcCtD
Nilotinib—Rash—Losartan—type 2 diabetes mellitus	3.92e-05	0.000185	CcSEcCtD
Nilotinib—Dermatitis—Losartan—type 2 diabetes mellitus	3.92e-05	0.000185	CcSEcCtD
Nilotinib—Headache—Losartan—type 2 diabetes mellitus	3.9e-05	0.000184	CcSEcCtD
Nilotinib—Asthenia—Ramipril—type 2 diabetes mellitus	3.83e-05	0.000181	CcSEcCtD
Nilotinib—Pruritus—Ramipril—type 2 diabetes mellitus	3.78e-05	0.000178	CcSEcCtD
Nilotinib—Nausea—Losartan—type 2 diabetes mellitus	3.7e-05	0.000174	CcSEcCtD
Nilotinib—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.65e-05	0.000172	CcSEcCtD
Nilotinib—Dizziness—Ramipril—type 2 diabetes mellitus	3.53e-05	0.000166	CcSEcCtD
Nilotinib—Vomiting—Ramipril—type 2 diabetes mellitus	3.39e-05	0.00016	CcSEcCtD
Nilotinib—Rash—Ramipril—type 2 diabetes mellitus	3.37e-05	0.000159	CcSEcCtD
Nilotinib—Dermatitis—Ramipril—type 2 diabetes mellitus	3.36e-05	0.000159	CcSEcCtD
Nilotinib—Headache—Ramipril—type 2 diabetes mellitus	3.34e-05	0.000158	CcSEcCtD
Nilotinib—Nausea—Ramipril—type 2 diabetes mellitus	3.17e-05	0.000149	CcSEcCtD
Nilotinib—LCK—Immune System—SRC—type 2 diabetes mellitus	1.27e-06	6.72e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—type 2 diabetes mellitus	1.27e-06	6.71e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—INS—type 2 diabetes mellitus	1.27e-06	6.7e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CALM1—type 2 diabetes mellitus	1.26e-06	6.68e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOE—type 2 diabetes mellitus	1.26e-06	6.66e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.25e-06	6.64e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—type 2 diabetes mellitus	1.25e-06	6.62e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.25e-06	6.59e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	1.24e-06	6.59e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOA1—type 2 diabetes mellitus	1.24e-06	6.58e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	1.24e-06	6.56e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.23e-06	6.52e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.22e-06	6.48e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.22e-06	6.48e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.22e-06	6.45e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.22e-06	6.44e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	1.22e-06	6.44e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	1.21e-06	6.41e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RELA—type 2 diabetes mellitus	1.21e-06	6.4e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	1.21e-06	6.39e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SRC—type 2 diabetes mellitus	1.2e-06	6.35e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	1.19e-06	6.32e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	1.19e-06	6.31e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.19e-06	6.3e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—type 2 diabetes mellitus	1.18e-06	6.26e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.18e-06	6.24e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	1.18e-06	6.23e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.17e-06	6.22e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—SRC—type 2 diabetes mellitus	1.17e-06	6.21e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.17e-06	6.2e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—type 2 diabetes mellitus	1.17e-06	6.19e-06	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—type 2 diabetes mellitus	1.17e-06	6.19e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.17e-06	6.19e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.17e-06	6.17e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.16e-06	6.15e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.16e-06	6.14e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.16e-06	6.12e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—type 2 diabetes mellitus	1.15e-06	6.11e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—type 2 diabetes mellitus	1.15e-06	6.1e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.15e-06	6.09e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.15e-06	6.07e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.15e-06	6.07e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.15e-06	6.07e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	1.15e-06	6.07e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	1.14e-06	6.06e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	1.14e-06	6.04e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	1.14e-06	6.01e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.14e-06	6.01e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SRC—type 2 diabetes mellitus	1.14e-06	6.01e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	1.13e-06	5.99e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.13e-06	5.97e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	1.13e-06	5.96e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—type 2 diabetes mellitus	1.12e-06	5.95e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.12e-06	5.95e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	1.12e-06	5.94e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.12e-06	5.92e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.12e-06	5.92e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.12e-06	5.92e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	1.12e-06	5.91e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—type 2 diabetes mellitus	1.11e-06	5.89e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.11e-06	5.88e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.11e-06	5.88e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.11e-06	5.88e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.11e-06	5.87e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.11e-06	5.86e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.11e-06	5.86e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.1e-06	5.81e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—type 2 diabetes mellitus	1.1e-06	5.8e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	1.09e-06	5.78e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—type 2 diabetes mellitus	1.09e-06	5.78e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—type 2 diabetes mellitus	1.09e-06	5.78e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.09e-06	5.78e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.09e-06	5.77e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	1.09e-06	5.76e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.09e-06	5.75e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.08e-06	5.74e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	1.08e-06	5.73e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.08e-06	5.72e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.08e-06	5.71e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.07e-06	5.69e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—INS—type 2 diabetes mellitus	1.07e-06	5.69e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.07e-06	5.68e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—type 2 diabetes mellitus	1.07e-06	5.66e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	1.07e-06	5.66e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—type 2 diabetes mellitus	1.07e-06	5.64e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	1.07e-06	5.64e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—type 2 diabetes mellitus	1.06e-06	5.64e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.06e-06	5.63e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	1.05e-06	5.58e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	1.05e-06	5.57e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.05e-06	5.57e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.05e-06	5.57e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—type 2 diabetes mellitus	1.05e-06	5.55e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RELA—type 2 diabetes mellitus	1.04e-06	5.53e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—type 2 diabetes mellitus	1.04e-06	5.52e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.04e-06	5.52e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.04e-06	5.5e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—type 2 diabetes mellitus	1.04e-06	5.5e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.04e-06	5.49e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	1.03e-06	5.48e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.03e-06	5.45e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—type 2 diabetes mellitus	1.03e-06	5.44e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SRC—type 2 diabetes mellitus	1.02e-06	5.42e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.02e-06	5.41e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.02e-06	5.39e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.02e-06	5.39e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.01e-06	5.37e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	1.01e-06	5.36e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	1.01e-06	5.34e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—type 2 diabetes mellitus	1.01e-06	5.34e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1e-06	5.31e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1e-06	5.31e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1e-06	5.31e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SRC—type 2 diabetes mellitus	1e-06	5.3e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	9.97e-07	5.28e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.96e-07	5.28e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.95e-07	5.27e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	9.91e-07	5.25e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—type 2 diabetes mellitus	9.89e-07	5.24e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.86e-07	5.22e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—type 2 diabetes mellitus	9.85e-07	5.22e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—type 2 diabetes mellitus	9.84e-07	5.21e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	9.84e-07	5.21e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—type 2 diabetes mellitus	9.83e-07	5.21e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	9.83e-07	5.2e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	9.79e-07	5.18e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	9.78e-07	5.18e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.75e-07	5.16e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	9.75e-07	5.16e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	9.7e-07	5.14e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—type 2 diabetes mellitus	9.63e-07	5.1e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—type 2 diabetes mellitus	9.58e-07	5.07e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	9.54e-07	5.05e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SRC—type 2 diabetes mellitus	9.49e-07	5.03e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	9.47e-07	5.01e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—type 2 diabetes mellitus	9.42e-07	4.99e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3R1—type 2 diabetes mellitus	9.42e-07	4.99e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.42e-07	4.99e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	9.39e-07	4.97e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	9.31e-07	4.93e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	9.31e-07	4.93e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	9.28e-07	4.91e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	9.28e-07	4.91e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.25e-07	4.9e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	9.21e-07	4.88e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	9.17e-07	4.86e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	9.17e-07	4.85e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.14e-07	4.84e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	9.13e-07	4.84e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—type 2 diabetes mellitus	9.13e-07	4.83e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	9.1e-07	4.82e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—type 2 diabetes mellitus	9.08e-07	4.81e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—type 2 diabetes mellitus	9.07e-07	4.8e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	9.07e-07	4.8e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	9.07e-07	4.8e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.97e-07	4.75e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—type 2 diabetes mellitus	8.96e-07	4.74e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.95e-07	4.74e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	8.92e-07	4.72e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.9e-07	4.71e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—type 2 diabetes mellitus	8.88e-07	4.7e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	8.85e-07	4.68e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.81e-07	4.66e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.78e-07	4.65e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	8.77e-07	4.65e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	8.74e-07	4.63e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	8.7e-07	4.61e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	8.69e-07	4.6e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	8.69e-07	4.6e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	8.67e-07	4.59e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	8.64e-07	4.58e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—type 2 diabetes mellitus	8.62e-07	4.56e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	8.57e-07	4.54e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—type 2 diabetes mellitus	8.55e-07	4.53e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.49e-07	4.49e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	8.34e-07	4.42e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.32e-07	4.41e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.27e-07	4.38e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SRC—type 2 diabetes mellitus	8.21e-07	4.35e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—type 2 diabetes mellitus	8.19e-07	4.34e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	8.08e-07	4.28e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—type 2 diabetes mellitus	8.08e-07	4.28e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8e-07	4.23e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	7.98e-07	4.22e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	7.98e-07	4.22e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	7.93e-07	4.2e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—type 2 diabetes mellitus	7.9e-07	4.18e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—type 2 diabetes mellitus	7.89e-07	4.18e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—type 2 diabetes mellitus	7.65e-07	4.05e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	7.62e-07	4.03e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	7.55e-07	4e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.49e-07	3.97e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	7.49e-07	3.97e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	7.47e-07	3.96e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	7.46e-07	3.95e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.45e-07	3.95e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	7.4e-07	3.92e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	7.36e-07	3.9e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.34e-07	3.89e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	7.3e-07	3.86e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—type 2 diabetes mellitus	7.28e-07	3.86e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	7.27e-07	3.85e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.19e-07	3.81e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	7.14e-07	3.78e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.06e-07	3.74e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—type 2 diabetes mellitus	6.97e-07	3.69e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	6.95e-07	3.68e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	6.95e-07	3.68e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	6.95e-07	3.68e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—type 2 diabetes mellitus	6.89e-07	3.65e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	6.85e-07	3.63e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	6.82e-07	3.61e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	6.79e-07	3.59e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—type 2 diabetes mellitus	6.75e-07	3.57e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	6.68e-07	3.54e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	6.65e-07	3.52e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	6.55e-07	3.47e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	6.55e-07	3.47e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	6.49e-07	3.44e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	6.49e-07	3.44e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	6.48e-07	3.43e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	6.4e-07	3.39e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—type 2 diabetes mellitus	6.4e-07	3.39e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	6.36e-07	3.37e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.36e-07	3.37e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.22e-07	3.3e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	6.14e-07	3.25e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	6.02e-07	3.19e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	5.99e-07	3.17e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	5.94e-07	3.14e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	5.91e-07	3.13e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.9e-07	3.12e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	5.83e-07	3.09e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	5.74e-07	3.04e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	5.72e-07	3.03e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	5.65e-07	2.99e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—type 2 diabetes mellitus	5.53e-07	2.93e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.1e-07	2.7e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	4.98e-07	2.64e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	4.88e-07	2.59e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	4.48e-07	2.37e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—type 2 diabetes mellitus	4.33e-07	2.29e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	4.28e-07	2.27e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	4.28e-07	2.27e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	3.92e-07	2.07e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	3.67e-07	1.94e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	3.2e-07	1.69e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	3.01e-07	1.59e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	2.99e-07	1.58e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.97e-07	1.04e-06	CbGpPWpGaD
